Functional compositions, conditioners and uses for treating or preventing bone and joint disorders

Abstract

The application discloses a functional composition, a conditioner and a use for treating or preventing bone and joint diseases. The composition of the functional composition comprises a first active component and a second active component, wherein the first active component comprises elastin peptide 1-500 mu g / mL, haematococcus pluvialis 40-20 mu g / mL, phyllanthus emblica 8-4 mu g / mL and mussel 1-500 mu g / mL in terms of concentration in the functional composition; and the second active component comprises broccoli water extract and / or boric acid substances. The application realizes the synergistic improvement of glycosaminoglycan and osteocalcin levels by scientific compounding, plays a protective role on joint, cartilage and bone health, and has natural, safe, good biocompatibility and no obvious side effects, and provides a kind of drug or a replacement scheme for bone disease treatment and prevention.

Description

Technical Field

[0001] This application relates to the field of biomedical technology, and in particular to functional compositions, conditioning agents and their use in the preparation of formulations for the treatment or prevention of bone and joint diseases. Background Technology

[0002] Bone and joint diseases are the most common orthopedic conditions and one of the three major orthopedic disciplines. They primarily include bone and joint diseases, such as arthritis and bone loss. These diseases are particularly prevalent in middle-aged and elderly individuals, and their symptoms often overlap. Clinical treatment mainly involves drug therapy or interventions. While nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac are the primary choice for relieving joint pain and inflammation, their long-term use carries clear safety risks, including gastrointestinal damage, increased risk of cardiovascular events, and nephrotoxicity, necessitating the development of safer alternatives. In the field of nutritional supplements, their effectiveness is generally limited. Therefore, developing drugs, nutritional supplements, and functional foods with good efficacy, low side effects, and high safety is crucial for the current treatment and intervention of bone and joint diseases. Summary of the Invention

[0003] Therefore, it is necessary to provide a functional composition for treating or preventing bone and joint diseases, which has the significant advantages of good efficacy, low side effects, and high safety.

[0004] In a first aspect, this application provides a functional composition for treating or preventing bone and joint diseases, the functional composition comprising a first active component and a second active component;

[0005] Based on the concentration in the functional composition for treating or preventing bone and joint diseases, the first active component comprises 1 μg / mL to 500 μg / mL of elastin peptide, 40 ng / mL to 20 μg / mL of Haematococcus pluvialis, 8 ng / mL to 4 μg / mL of Phyllanthus emblica, and 1 μg / mL to 500 μg / mL of mussel.

[0006] The mussels are prepared using mussel meat as the raw material;

[0007] The second active component includes one or more of broccoli water extract and boric acid substances.

[0008] In some embodiments, the amount of broccoli water extract added is 200 ng / mL to 100 μg / mL, based on the concentration in the functional composition for treating or preventing bone and joint diseases; and / or, the amount of boric acid added is 2 ng / mL to 10 μg / mL.

[0009] In some embodiments, the first active component comprises, at a concentration in the functional composition for treating or preventing bone and joint diseases, 100 μg / mL-500 μg / mL elastin, 4 μg / mL-20 μg / mL Haematococcus pluvialis, 1 μg / mL-4 μg / mL Phyllanthus emblica, and 100 μg / mL-500 μg / mL mussels; and / or, the amount of broccoli water extract added is 10 μg / mL-100 μg / mL; and / or, at a concentration in the functional composition, the amount of boric acid added is 1 μg / mL-10 μg / mL.

[0010] In some embodiments, the amla includes amla powder; and / or, the broccoli water extract includes broccoli seed water extract; and / or, the mussel includes green-lipped mussel powder, prepared from the meat of green-lipped mussels; and / or, the boric acid includes glycine boron; and / or, the Haematococcus pluvialis includes one or more of Haematococcus pluvialis raw materials and their extracts.

[0011] In some embodiments, the second active component includes broccoli water extract and boric acid substances.

[0012] In a second aspect, this application also provides a conditioning agent comprising the functional composition provided in the first aspect for treating or preventing bone and joint diseases.

[0013] In some embodiments, the conditioning agent is administered topically and / or orally; and / or, the dosage form of the conditioning agent includes suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

[0014] Thirdly, this application also provides the use of functional compositions and / or conditioning agents in the preparation of formulations for the treatment or prevention of bone diseases; the functional compositions include the functional compositions for the treatment or prevention of bone and joint diseases provided in the first aspect, and the conditioning agents include the conditioning agents provided in the second aspect.

[0015] In some embodiments, the skeletal disease includes bone disease and / or joint disease.

[0016] In some embodiments, the bone disease includes bone loss diseases; and / or, the joint disease includes osteoarthritis.

[0017] Compared with traditional technologies, the technical solution of this application has the following advantages:

[0018] This application provides a class of functional compositions for treating or preventing bone and joint diseases. These compositions include specific amounts of elastin peptides, Haematococcus pluvialis, Phyllanthus emblica, and mussels, and are synergistically formulated with one or more of broccoli water extract and boric acid substances to promote the production of glycosaminoglycans in chondrocytes and osteocalcin in osteoblasts, thereby achieving therapeutic and preventative effects on bone diseases. Furthermore, the raw materials of this functional composition for treating or preventing bone and joint diseases are naturally derived, safe, and biocompatible. While achieving significant therapeutic and preventative effects on bone diseases, it has no obvious side effects, providing a class of drugs or alternatives for the treatment and prevention of bone diseases. Detailed Implementation

[0019] To facilitate understanding of the present invention, preferred embodiments are provided below to provide a more complete description of the invention. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to enable a thorough and complete understanding of the disclosure of the present invention.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.

[0021] As used herein, "optional," "optional," and "optional" refer to either "with" or "without" parallel options. If multiple "optional" entries appear in a technical solution, each "optional" entry is independent unless otherwise specified and there are no contradictions or mutual constraints. The term "and / or" as used herein includes any and all combinations of one or more related listed items. Unless otherwise specified, "multiple," "multiple," etc., as used herein refer to a quantity greater than 2 or equal to 2; for example, "one or more" indicates one, two, or more than two. In open-ended technical features or solutions described herein using words such as "containing," "including," and "comprising," unless otherwise specified, additional members beyond the listed members are not excluded. This can be considered as providing both a closed-ended feature or solution consisting of the listed members and an open-ended feature or solution that includes additional members beyond the listed members.

[0022] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," etc., serve only as a non-exhaustive enumeration and should be understood not to constitute a closed limitation on quantity.

[0023] Unless otherwise specified, all embodiments and optional embodiments of this application can be combined to form new technical solutions.

[0024] Osteoarthritis and osteoarthritis are common bone diseases with high incidence rates and often intertwined, especially among the elderly, posing a significant and complex challenge to this population. Osteoarthritis primarily involves the degeneration of articular cartilage, while osteoporosis leads to the destruction of bone microstructure. Pathologically, they influence each other; the decline in bone biomechanical properties caused by osteoporosis exacerbates joint load imbalance, and joint inflammation can also disrupt bone metabolic homeostasis.

[0025] Glycosaminoglycans are the main structural components of the cartilage matrix framework, playing an irreplaceable supporting and protective role in joint function. Due to the large number of negative charges carried on their molecular chains, glycosaminoglycans possess strong hydrophilicity, capable of binding water molecules far exceeding their own weight to form a highly hydrated gel structure. This provides cartilage with excellent compressive elasticity, playing a crucial role in cushioning and shock absorption when the joint is subjected to mechanical loads. Simultaneously, glycosaminoglycans bind tightly to the type II collagen network, stabilizing the spatial conformation of collagen fibers through electrostatic repulsion, jointly resisting friction and impact during daily activities and preventing premature cartilage wear and degeneration. At the bioactivity level, glycosaminoglycans such as chondroitin sulfate can inhibit the release of key inflammatory pathways (such as NF-κB) and their mediated pro-inflammatory factors (such as IL-1β and TNF-α), thereby reducing synovial inflammation. They also provide important precursor substances for chondrocytes, supporting proteoglycan synthesis and promoting the self-renewal and repair of cartilage tissue.

[0026] Osteocalcin is a non-collagenous protein specifically synthesized by osteoblasts, playing a crucial role in maintaining bone health and mineralization. Its core function, as a vitamin K-dependent protein, after γ-carboxylation modification, allows it to bind with high affinity to calcium ions in hydroxyapatite, precisely guiding calcium deposition in the bone matrix and preventing pathological calcium deposition in blood vessel walls or soft tissues. This is essential for maintaining bone density and strength. Therefore, effectively activating osteocalcin is a key step in achieving high-quality bone mineralization and preventing osteoporosis.

[0027] However, current mainstream interventions employ drug therapy, such as nonsteroidal anti-inflammatory drugs (NSAIDs), which have significant safety concerns, including substantial side effects. Therefore, there is an urgent need to develop drugs or alternatives that are both safe and effective, such as nutritional supplements or functional foods.

[0028] This application aims to develop a functional composition for the treatment or prevention of bone and joint diseases, which has the advantages of good efficacy, low side effects and safety.

[0029] In a first aspect, this application provides a functional composition for treating or preventing bone and joint diseases, the composition comprising a first active component and a second active component;

[0030] Based on the concentration in the functional composition for treating or preventing bone and joint diseases, the first active component comprises 1 μg / mL to 500 μg / mL of elastin peptide, 40 ng / mL to 20 μg / mL of Haematococcus pluvialis, 8 ng / mL to 4 μg / mL of Phyllanthus emblica, and 1 μg / mL to 500 μg / mL of mussel.

[0031] The mussels are prepared using mussel meat as the raw material;

[0032] The second active component includes one or more of broccoli water extract and boric acid substances.

[0033] This application uses a functional system to screen for a first active component containing elastin peptides, Haematococcus pluvialis, and Phyllanthus emblica, and a second active component containing one or more of broccoli water extract, mussels, and boric acid substances. Through the synergistic effect of the first and second active substances, it achieves the treatment and intervention of bone diseases and specifically protects the health of joints and bones.

[0034] As a non-limiting example, the amla includes amla powder. It is understood that the amla powder is obtained by pulverizing amla raw materials.

[0035] As a non-limiting example, the Haematococcus pluvialis includes one or more of Haematococcus pluvialis raw materials and their extracts. It is understood that the Haematococcus pluvialis raw material extracts include water extracts and / or alcohol extracts.

[0036] As a non-limiting example, the broccoli water extract includes broccoli seed water extract.

[0037] As a non-limiting example, the mussel powder includes freeze-dried mussel powder. Further, the mussel powder is selected from freeze-dried green-lipped mussel powder.

[0038] As a non-limiting example, the borate substances include glycine boron.

[0039] In some embodiments, the amount of broccoli water extract added, based on the concentration in the functional composition for treating or preventing bone and joint diseases, is 200 ng / mL to 100 μg / mL, including but not limited to 200 ng / mL, 500 ng / mL, 1 μg / mL, 5 μg / mL, 10 μg / mL, 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL, 60 μg / mL, 70 μg / mL, 80 μg / mL, 90 μg / mL, 100 μg / mL, or any combination thereof and values ​​within that range. Further, based on the concentration in the functional composition for treating or preventing bone and joint diseases, the amount of broccoli aqueous extract added is 10 μg / mL to 100 μg / mL, including but not limited to 10 μg / mL, 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL, 60 μg / mL, 70 μg / mL, 80 μg / mL, 90 μg / mL, 100 μg / mL, or any range formed by both of the foregoing and values ​​within such ranges. Even further, the amount of broccoli aqueous extract added is 80 μg / mL to 100 μg / mL.

[0040] In some embodiments, the amount of boric acid added, based on the concentration in the functional composition for treating or preventing bone and joint diseases, is 2 ng / mL to 10 μg / mL, including but not limited to 2 ng / mL, 10 ng / mL, 50 ng / mL, 100 ng / mL, 500 ng / mL, 1 μg / mL, 2 μg / mL, 3 μg / mL, 4 μg / mL, 5 μg / mL, 6 μg / mL, 7 μg / mL, 8 μg / mL, 9 μg / mL, 10 μg / mL, or any range formed by both of the foregoing and values ​​within such ranges. Further, based on the concentration in the functional composition for treating or preventing bone and joint diseases, the amount of boric acid added is 1 μg / mL to 10 μg / mL.

[0041] In some preferred embodiments, the first active component, at a concentration in the functional composition for treating or preventing bone and joint diseases, comprises 100 μg / mL-500 μg / mL elastin, 4 μg / mL-20 μg / mL Haematococcus pluvialis, 1 μg / mL-4 μg / mL Phyllanthus emblica, and 100 μg / mL-500 μg / mL mussels. Further, at a concentration in the functional composition for treating or preventing bone and joint diseases, the first active component comprises 400 μg / mL-500 μg / mL elastin, 15 μg / mL-20 μg / mL Haematococcus pluvialis, 2 μg / mL-4 μg / mL Phyllanthus emblica, and 100 μg / mL-500 μg / mL mussels.

[0042] In some embodiments, the second active component includes broccoli water extract and boric acid substances.

[0043] In some preferred embodiments, the second active component, at a concentration of 200 ng / mL to 100 μg / mL of broccoli aqueous extract and 2 ng / mL to 10 μg / mL of boric acid, is included in the functional composition for treating or preventing bone and joint diseases. Further, at a concentration of 10 μg / mL to 100 μg / mL of broccoli aqueous extract and 1 μg / mL to 10 μg / mL of boric acid, the second active component, at a concentration of 80 μg / mL to 100 μg / mL of broccoli aqueous extract and 1 μg / mL to 10 μg / mL of boric acid, is included in the functional composition for treating or preventing bone and joint diseases.

[0044] In some preferred embodiments, the functional composition for treating or preventing bone and joint diseases comprises, in concentrations of 1 μg / mL to 500 μg / mL elastin peptide, 40 ng / mL to 20 μg / mL Haematococcus pluvialis, 8 ng / mL to 4 μg / mL Phyllanthus emblica, 1 μg / mL to 500 μg / mL mussel, 200 ng / mL to 100 μg / mL broccoli water extract, and 2 ng / mL to 10 μg / mL boric acid.

[0045] In some preferred embodiments, the functional composition for treating or preventing bone and joint diseases comprises, in concentrations of 100 μg / mL to 500 μg / mL elastin peptides, 4 μg / mL to 20 μg / mL Haematococcus pluvialis, 1 μg / mL to 4 μg / mL Phyllanthus emblica, 100 μg / mL to 500 μg / mL mussels, 10 μg / mL to 100 μg / mL broccoli water extract, and 1 μg / mL to 10 μg / mL boric acid.

[0046] In some preferred embodiments, the functional composition for treating or preventing bone and joint diseases comprises, in concentrations of 400 μg / mL-500 μg / mL elastin, 15 μg / mL-20 μg / mL Haematococcus pluvialis, 2 μg / mL-4 μg / mL Phyllanthus emblica, 100 μg / mL-500 μg / mL mussels, 80 μg / mL-100 μg / mL broccoli water extract, and 1 g / mL-10 μg / mL boric acid.

[0047] The functional composition of this application for the treatment or prevention of bone and joint diseases exerts its therapeutic effect through a synergistic effect between the first and second active components. The first active ingredient, comprising elastin peptides, Haematococcus pluvialis, Phyllanthus emblica, and mussels, provides the basic components of the composition. When combined with one or more components from broccoli water extract and boric acid derivatives, it significantly enhances the composition's bioactivity, including: inducing endogenous antioxidant activity, improving bone's resistance to oxidative stress damage, inhibiting key pro-inflammatory signaling pathways, producing excellent antioxidant and anti-inflammatory activities, helping to alleviate potential inflammatory bone damage, reducing the disruption of bone homeostasis by chronic low-grade inflammation, and demonstrating excellent efficacy in the treatment and intervention of degenerative bone and joint diseases such as osteoarthritis. Simultaneously, it improves joint function, protects subchondral bone from inflammatory erosion, and rapidly relieves joint inflammation and pain. Furthermore, it synergistically increases plasma calcium and magnesium levels and reduces urinary calcium loss, promoting bone health.

[0048] The functional composition provided in this application for the treatment or prevention of bone and joint diseases can significantly increase the level of glycosaminoglycans in chondrocytes, significantly reduce osteoarthritis inflammation, and simultaneously significantly increase the level of osteocalcin in osteocytes, promoting bone health and effectively treating and preventing osteoporosis and other bone loss diseases. Furthermore, the raw materials of the functional composition of this application are naturally sourced and environmentally friendly, with good compatibility and no obvious side effects, and can serve as an alternative or supplementary preparation to current drug treatments for bone diseases.

[0049] In a second aspect, this application also provides a conditioning agent comprising the functional composition provided in the first aspect for treating or preventing bone and joint diseases.

[0050] In some embodiments, the conditioning agent may be applied topically and / or orally.

[0051] In some embodiments, the dosage form of the conditioning agent includes suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

[0052] The conditioning agent provided in this application has excellent therapeutic and / or preventive effects on bone diseases, and is effective against degenerative osteoarthritis and bone loss diseases. It is not limited to use as a medicine or nutritional supplement.

[0053] Thirdly, this application also provides the use of a class of functional compositions and / or conditioning agents in the preparation of formulations for the treatment or prevention of bone diseases, wherein the functional compositions include the functional compositions for the treatment or prevention of bone and joint diseases provided in the first aspect, and the conditioning agents include the conditioning agents provided in the second aspect.

[0054] This application significantly enhances the functional activity of the composition by combining the first and second active components, synergistically improving the composition's effects on reducing cartilage and joint inflammation, improving bone quality, increasing glycosaminoglycan concentration in chondrocytes and osteocalcin in osteoblasts, and promoting the improvement of osteoarthritis, high-quality bone mineralization, and the prevention and treatment of osteoporosis. Furthermore, the functional composition of this application for the treatment or prevention of bone and joint diseases uses natural and environmentally friendly raw materials, has good compatibility, and no obvious side effects, making it a viable alternative or supplementary formulation to current drug treatments for bone diseases.

[0055] In some embodiments, the skeletal disease includes bone disease and / or joint disease.

[0056] In some embodiments, the bone disease includes bone loss diseases and / or bone metabolism disorders; the bone loss diseases include osteoporosis.

[0057] In some embodiments, the joint disease includes osteoarthritis and / or articular cartilage degeneration.

[0058] For experimental parameters not specified in the following specific embodiments, please refer to the guidelines given in this application document first, or refer to experimental manuals or other experimental methods known in the art, or refer to the experimental conditions recommended by the manufacturer.

[0059] The raw materials and reagents involved in the following specific embodiments can be obtained commercially or prepared by those skilled in the art using known methods.

[0060] The specific sources and types of raw materials and cells involved in the specific embodiments of this application are as follows:

[0061] Elastin peptides were purchased from Hainan Huayan Collagen Technology Co., Ltd.; Haematococcus pluvialis was purchased from Dalian Yinuo; Broccoli seed water extract was purchased from Ganzhou Huahan Biotechnology Co., Ltd.; Phyllanthus emblica powder was purchased from Carelife; Green-lipped mussels were purchased from AROMA, New Zealand; and all other chemical reagents were conventional reagents.

[0062] Example 1 Functional Composition

[0063] The functional composition formulations provided in this embodiment are shown in Table 1:

[0064] Table 1: Formulation of Functional Compositions

[0065]

[0066] The above 15 formulations were mixed with complete cell culture medium according to the formulation amounts to prepare functional compositions.

[0067] Experimental Example 1: Effects of Functional Compositions on Cell Viability

[0068] In this experiment, immortalized human chondrocytes (purchased from Zhejiang Meisen Cell Technology Co., Ltd.) and human osteoblast cell line hFOB1.19 (purchased from Shanghai Qingqi Biotechnology Development Co., Ltd.) were used as test subjects to detect the effect of different formulations of functional compositions on cell viability. The cell viability CCK8 assay kit was purchased from Dojin Chemical Co., Ltd., Japan.

[0069] The specific experimental steps are as follows: Chondrocytes in the logarithmic growth phase were collected and digested. The chondrocytes were then used to prepare a chondrocyte suspension in DMEM / F-12 complete medium (purchased from Zhejiang Meisen Cell Technology Co., Ltd., catalog number CTCC-002-004) containing 10% fetal bovine serum and 1% penicillin and streptomycin. Osteoblasts were seeded into 96-well plates using DMEM complete medium (purchased from Gibco, catalog number 3144500), with a cell count of 1.1 × 10⁶ cells per well. 4 / well. Cells were cultured overnight at 37°C in a 5% CO2 incubator. When cell confluence was approximately 80%, the functional composition was diluted with complete culture medium according to the concentrations specified in Table 1. A blank control group containing only culture medium was also included. The treated cells were then placed back into the incubator for another 24 hours. The original culture medium was replaced with medium containing 10% CCK-8. The 96-well plate was then placed in the incubator for 30 minutes, and the OD value of each well was measured at 450 nm. Six replicates were performed for each concentration. The cell proliferation and survival rate of different formulations of the functional composition were calculated according to formula (1).

[0070] (1)

[0071] The results obtained based on the above test methods are shown in Table 2:

[0072] Table 2: Toxicity of Functional Compositions on Human Cartilage and Osteoblasts

[0073]

[0074] As shown in Table 2, the functional compositions of the 15 formulations have no toxic effects on human chondrocytes and osteoblasts.

[0075] Experimental Example 2: Effect of Functional Compositions on Glycosaminoglycans in a Chondrocyte Osteoarthritis Model

[0076] In this study, immortalized human chondrocytes were used as the test subject to investigate the effects of different drug combinations on glycosaminoglycans in an etoposide (purchased from MCE, catalog number HY-13629)-induced osteoarthritis model. The glycosaminoglycan assay kit was purchased from Shanghai Keabob Biotechnology Co., Ltd., catalog number CB11354-Hu.

[0077] The specific experimental steps are as follows: Human chondrocytes were divided into groups of 5 × 10⁻⁶ cells. 6 Cells were seeded in 6-well plates and cultured overnight at 37°C with 5% CO2. When cell confluence reached approximately 80%, drug treatment was administered. The experiment included a blank control group, a model group (etoposide, 25 mM), a positive control group (glucosamine, 1 mM), and functional composition treatment groups as shown in Table 1. After 24 hours of incubation, cell supernatant was collected and centrifuged at 2000-3000 rpm for 20 minutes. The supernatant was then used as the test sample.

[0078] The concentration of glycosaminoglycans was detected using an enzyme-linked immunosorbent assay (ELISA). For detailed procedures, please refer to the instruction manual.

[0079] The test results are shown in Table 3:

[0080] Table 3: Effects of functional compositions on glycosaminoglycan concentration in chondrocytes

[0081]

[0082] As shown in Table 3, etoposide induction of chondrocytes significantly reduced glycosaminoglycan concentration, while glycosaminoglycan production significantly increased in the positive control group, indicating the successful establishment of the osteoarthritis model. Formulas 1-9 significantly enhanced glycosaminoglycan production under these model conditions. In contrast, formulas 1-6 showed weaker effects on glycosaminoglycan production in the osteoarthritis model, and some formulas did not show significant changes, demonstrating a synergistic effect among the components in the formulas provided in this application.

[0083] Experimental Example 3: Effect of Functional Compositions on Osteocalcin in an Osteoblast Osteoporosis Model

[0084] In this experiment, the human osteoblast cell line hFOB1.19 (purchased from Shanghai Qingqi Biotechnology Development Co., Ltd.) was used as the test subject to detect the effects of different drug combinations on osteocalcin in a D-galactose (purchased from Aladdin, catalog number G100369)-induced osteoporosis model. The human osteocalcin assay kit was purchased from Shanghai Keabob Biotechnology Co., Ltd., catalog number CB10653-Hu.

[0085] The specific experimental steps are as follows: Human osteoblasts were divided into groups of 6 × 10⁻⁶ cells. 6 Cells were seeded in 6-well plates and cultured overnight at 37°C with 5% CO2. When cell confluence was approximately 80%, drug treatment was administered. The experiment included a blank control group, a model group (200 mM D-galactose), a positive control group (10 μM teriparatide, purchased from MCE, catalog number HY-P0059), and functional composition treatment groups as shown in Table 1. After 24 hours, cell supernatant was collected and centrifuged at 2000-3000 rpm for 20 minutes. The supernatant was used as the test sample.

[0086] The osteocalcin concentration was detected using an enzyme-linked immunosorbent assay (ELISA). See the instruction manual for detailed procedures.

[0087] The test results are shown in Table 4:

[0088] Table 4: Effects of functional compositions on osteocalcin concentration in osteoblasts

[0089]

[0090] As shown in Table 4, D-galactose-induced osteoblasts significantly reduced osteocalcin concentration, while the positive control group showed significantly increased osteocalcin production, indicating the successful establishment of the osteoporosis model. Formulas 1-9 significantly enhanced osteocalcin production under these model conditions, thus improving osteoporosis. In contrast, formulas 1-6 had a weaker effect on osteocalcin concentration, with some formulas showing no effect at all, indicating that formulas 1-6 did not significantly improve the osteoporosis model.

[0091] In summary, based on the results in Tables 3 and 4, this application demonstrates that the scientific formulation of multiple components achieves a synergistic effect, synergistically promoting the production of glycosaminoglycans in chondrocytes and osteocalcin production in osteoblasts, thereby achieving therapeutic and preventative effects on bone diseases. Furthermore, the raw materials in the formulation provided by this application are naturally sourced, safe, and biocompatible. While achieving significant therapeutic and preventative effects on bone diseases, it has no obvious side effects, providing a class of drugs or alternatives for the treatment and prevention of bone diseases.

[0092] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0093] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. A functional composition for treating or preventing bone and joint diseases, characterized in that, The active component of the functional composition is composed of a first active component and a second active component; Based on the concentration in the functional composition, the first active component is 400 μg / mL-500 μg / mL of elastin peptide, 15 μg / mL-20 μg / mL of Haematococcus pluvialis, 2 μg / mL-4 μg / mL of Phyllanthus emblica, and 100 μg / mL-500 μg / mL of mussel. The mussels are prepared using mussel meat as raw material; Based on the concentration in the functional composition, the second active component is 80 μg / mL-100 μg / mL of broccoli water extract and 1 μg / mL-10 μg / mL of boric acid.

2. The functional composition for treating or preventing bone and joint diseases according to claim 1, characterized in that, The active component of the functional composition is composed of a first active component and a second active component; Based on the concentration in the functional composition, the first active component is 500 μg / mL elastin peptide, 20 μg / mL Haematococcus pluvialis, 4 μg / mL Phyllanthus emblica and 500 μg / mL mussel. The mussels are prepared using mussel meat as raw material; Based on the concentration in the functional composition, the second active component is 100 μg / mL of broccoli water extract and 10 μg / mL of boric acid.

3. The functional composition for treating or preventing bone and joint diseases according to claim 1, characterized in that, The active component of the functional composition is composed of a first active component and a second active component; Based on the concentration in the functional composition, the first active component is 500 μg / mL elastin peptide, 20 μg / mL Haematococcus pluvialis, 4 μg / mL Phyllanthus emblica and 100 μg / mL mussel. The mussels are prepared using mussel meat as raw material; Based on the concentration in the functional composition, the second active component is 100 μg / mL of broccoli water extract and 10 μg / mL of boric acid.

4. The functional composition for treating or preventing bone and joint diseases according to claim 1, characterized in that, The active component of the functional composition is composed of a first active component and a second active component; Based on the concentration in the functional composition, the first active component is 500 μg / mL elastin peptide, 20 μg / mL Haematococcus pluvialis, 4 μg / mL Phyllanthus emblica and 500 μg / mL mussel. The mussels are prepared using mussel meat as raw material; Based on the concentration in the functional composition, the second active component is 100 μg / mL of broccoli water extract and 1 μg / mL of boric acid.

5. A functional composition for treating or preventing bone and joint diseases, characterized in that, The active component of the functional composition is composed of a first active component and a second active component; Based on the concentration in the functional composition, the first active component is 100 μg / mL of elastin peptide, 4 μg / mL of Haematococcus pluvialis, 4 μg / mL of Phyllanthus emblica and 100 μg / mL of mussel. The mussels are prepared using mussel meat as raw material; Based on the concentration in the functional composition, the second active component is 100 μg / mL of broccoli water extract and 1 μg / mL of boric acid.

6. The functional composition for treating or preventing bone and joint diseases according to any one of claims 1 to 5, characterized in that, The amla seed includes amla powder; and / or, the broccoli water extract includes broccoli seed water extract; and / or, the mussel includes green-lipped mussel powder, prepared from the meat of green-lipped mussels; and / or, the boric acid includes glycine boron; and / or, the Haematococcus pluvialis includes one or more of Haematococcus pluvialis raw materials and their extracts.

7. A conditioning agent, characterized in that, The conditioning agent includes the functional composition for treating or preventing bone and joint diseases as described in any one of claims 1 to 6.

8. The conditioner according to claim 7, characterized in that, The application of the conditioning agent includes external and / or internal use; and / or, the dosage form of the conditioning agent includes suspension, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

9. The use of functional compositions and / or conditioning agents in the preparation of formulations for the treatment or prevention of bone diseases, characterized in that, The functional composition includes the functional composition for treating or preventing bone and joint diseases as described in any one of claims 1 to 6, and the conditioning agent includes the conditioning agent as described in claim 7 or 8.

10. The use of the functional composition and / or conditioning agent according to claim 9 in the preparation of formulations for the treatment or prevention of bone diseases, characterized in that, The skeletal diseases include bone diseases and / or joint diseases.

11. The use of the functional composition and / or conditioning agent according to claim 10 in the preparation of formulations for the treatment or prevention of bone diseases, characterized in that, The bone diseases include bone loss diseases; and / or, the joint diseases include osteoarthritis.

Images